Thermo Announces PharmaFluidics Acquisition
Thermo Fisher Scientific (Waltham, Massachusetts, USA) has announced the acquisition of Belgium-based PharmaFluidics, the developer of the μPAC range of micro-chip-based chromatography columns.
The micro-pillar array portfolio of columns enhance liquid chromatography (LC) performance in biomarker, proteomics, and drug research and development applications. The columns are formed by carefully etching away the interstitial volumes out of a solid silicon wafer, leaving an array of pillars. The resulting channels are folded onto a small footprint by concatenating bed segments with optimized flow distributors that limit peak dispersion. This creates a stationary phase support structure that is organized in a reproducible,
ordered pattern.
“LC is a key analytical technique across numerous applications, and its accuracy, reproducibility, and robustness is critical to the delivery of meaningful results,” said Kent Davidson, Vice President and General Manager, High Performance Chromatography Solutions, Chromatography and Mass Spectrometry, Thermo Fisher Scientific. “Columns are an essential part of these workflows, and the next-generation μPAC columns push this element to a new level through innovative pillar array technology, improving the quality
of data.”
For more information, please visit: https://corporate.thermofisher.com or www.pharmafluidics.com
AI and GenAI Applications to Help Optimize Purification and Yield of Antibodies From Plasma
October 31st 2024Deriving antibodies from plasma products involves several steps, typically starting from the collection of plasma and ending with the purification of the desired antibodies. These are: plasma collection; plasma pooling; fractionation; antibody purification; concentration and formulation; quality control; and packaging and storage. This process results in a purified antibody product that can be used for therapeutic purposes, diagnostic tests, or research. Each step is critical to ensure the safety, efficacy, and quality of the final product. Applications of AI/GenAI in many of these steps can significantly help in the optimization of purification and yield of the desired antibodies. Some specific use-cases are: selecting and optimizing plasma units for optimized plasma pooling; GenAI solution for enterprise search on internal knowledge portal; analysing and optimizing production batch profitability, inventory, yields; monitoring production batch key performance indicators for outlier identification; monitoring production equipment to predict maintenance events; and reducing quality control laboratory testing turnaround time.
